We have located links that may give you full text access.
Perception of burden of oral and inhaled corticosteroid adverse effects on asthma-specific quality of life.
Annals of Allergy, Asthma & Immunology 2023 August 28
BACKGROUND: A multistakeholder core outcome set created for asthma trials showed that asthma specific quality of life (QoL) was a critically meaningful outcome. However, the definition and how to measure it was undetermined. The adverse effects (AEs) of corticosteroids may be a vital clinical trial outcome. Yet, the AE burden from the patient perspective has not yet been elucidated in an asthma population.
OBJECTIVE: To characterize patient burden of AEs in oral (OCS) and inhaled corticosteroids (ICS) and how this relates to QoL within an asthma population.
METHODS: We utilized a convergent parallel mixed-methods design with quantitative surveys of known ICS and OCS AEs which were distributed through the Allergy & Asthma Network's database, social channels, and Asthma UK's newsletter. Participants rated the AEs that were (1) most burdensome and (2) most desired to be eliminated. Qualitative interviews and focus groups were performed to better understand patient views on barriers reported in the quantitative data, and to identify patient important barriers which were not a part of the quantitative survey.
RESULTS: The three most burdensome AEs for OCS were decreased bone mineral density, infectious complications, and weight gain, whereas weight gain was the most desired to be eliminated. The three most burdensome AEs for ICS were pneumonia, hoarse voice, and oral thrush with concordant results for the most desired to be eliminated. In the focus groups, OCS AEs were concordant with quantitative findings. Focus groups identified unmeasured psychosocial effects, such as embarrassment.
CONCLUSION: The most burdensome AEs may not be the AEs that would cause patients to stop therapy. Furthermore, qualitative focus groups suggest a psychosocial burden associated with ICS, which needs further investigation.
OBJECTIVE: To characterize patient burden of AEs in oral (OCS) and inhaled corticosteroids (ICS) and how this relates to QoL within an asthma population.
METHODS: We utilized a convergent parallel mixed-methods design with quantitative surveys of known ICS and OCS AEs which were distributed through the Allergy & Asthma Network's database, social channels, and Asthma UK's newsletter. Participants rated the AEs that were (1) most burdensome and (2) most desired to be eliminated. Qualitative interviews and focus groups were performed to better understand patient views on barriers reported in the quantitative data, and to identify patient important barriers which were not a part of the quantitative survey.
RESULTS: The three most burdensome AEs for OCS were decreased bone mineral density, infectious complications, and weight gain, whereas weight gain was the most desired to be eliminated. The three most burdensome AEs for ICS were pneumonia, hoarse voice, and oral thrush with concordant results for the most desired to be eliminated. In the focus groups, OCS AEs were concordant with quantitative findings. Focus groups identified unmeasured psychosocial effects, such as embarrassment.
CONCLUSION: The most burdensome AEs may not be the AEs that would cause patients to stop therapy. Furthermore, qualitative focus groups suggest a psychosocial burden associated with ICS, which needs further investigation.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app